B7-33B72

Images are illustrative. Actual specifications are as selected and confirmed in writing.

Repair & Recovery Research

B7-33

Fibrosis regulation

B7-33 specifications and reference prices. Select a specification to add it to your cart.

2mg*10vials
Reference priceUS$105

For laboratory research only. Not for human or veterinary use.

COA 检测报告 / Reports

Compare all specifications & reference prices
SKUSpecification / packReference price (USD)
B722mg*10vialsUS$105
B71010mg*10vialsUS$358

Temporarily sold-out specifications can still be added to an inquiry to ask about restocking. An inquiry is not an order or an agreed price.

RESEARCH FOCUS

Main Uses & FAQs

This page organizes directly relevant information on B7-33 regarding fibrosis regulation. First, review the research questions and findings, then verify the population or species, study formulations, and scope of interpretation.

Main TopicsFibrosis regulation
USAGE REFERENCE

B7-33 · Usage reference (for research purposes)

The following presents common research-context references for reconstitution, storage, dosage and cycles. The following presents common references in research settings. This page does not constitute advice for use in humans or animals.

🧪Reconstitution

Suggested Diluent
Bacteriostatic Water (containing 0.9% benzyl alcohol); some peptides may use sterile water or acetic acid to aid dissolution. See the individual product descriptions.
Diluent Volume
Slowly introduce the diluent along the vial wall until the lyophilized powder is covered. A common example is 5 mg reconstituted with 2 mL of bacteriostatic water, yielding approximately 2.5 mg/mL. Referenced reconstitution volumes are approximately 1–2.5 mL, with 2 mL commonly used. It is suggested to select and record a fixed volume based on the COA supplied with the purchase.
Handling Notes
Introduce the diluent slowly along the vial wall rather than directly onto the lyophilized powder. Leave it for 60–90 seconds to dissolve naturally; do not shake vigorously.

💾Storage

Unreconstituted Lyophilized Powder
Refrigerate at 2–8°C, protected from light; avoid repeated freeze–thaw cycles.
After Reconstitution
Refrigerate at 2–8°C; a common recommendation is touse within 28 days; do not freeze.
Transport
For short periods, use insulated packaging with ice packs; avoid high temperatures and direct light.

📏Dosage Reference (Research)

Purpose / SettingCommon Reference
ExplanationFibrosis regulation study

Note: The above describes common research-context references, rather than clinical recommendations. Refer to the batch COA and research protocol. For research use only; not for human or animal use.

Research SummaryKey Findings

What research findings does B7-33 have in fibrosis regulation?

B7-33 reduces left ventricular fibrosis and improves some cardiovascular tissue indicators. Another study reports: reduces cell death and adverse remodeling, preserves heart function.[1] ↗ [2] ↗

Before ReadingStudy populations, species, formulations and delivery conditions each have a defined scope. Research on an ingredient does not establish that this site's product batches have been validated for efficacy in humans or veterinary use.
3 Main ReferencesSorted by First Publication Date ↓
Animal Study2023REF. 01

What does the study of left ventricular fibrosis in cardiomyopathy models indicate?

Research Findings

B7-33 reduces left ventricular fibrosis and improves some cardiovascular tissue indicators.[1] ↗

Study Design

Mouse isoproterenol cardiomyopathy model

Scope & Limitations

Preclinical; not equivalent to efficacy in human heart failure.

View the Article Title and Full Citation+

The single-chain relaxin mimetic, B7-33, maintains the cardioprotective effects of relaxin and more rapidly reduces left ventricular fibrosis compared to perindopril in an experimental model of cardiomyopathy.

Alam F, Gaspari TA, Kemp-Harper BK, Low E, Aw A, Ferens D, Spizzo I, Jefferis AM, Praveen P, Widdop RE, Bathgate RAD, Hossain MA, Samuel CS.

Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie · Volume/Issue Year 2023
First published 2023-02-06 · PMID 36753958
DOI 10.1016/j.biopha.2023.114370

Animal / experimental studies2020 · Historical basic researchREF. 02

What changes occur in adverse remodeling in myocardial infarction mice?

Research Findings

Reduce cell death and adverse remodeling, preserve cardiac function.[2] ↗

Study Design

Mouse myocardial infarction and myocardial cells

Scope & Limitations

Animal mechanism studies.

View the Article Title and Full Citation+

B7-33, a Functionally Selective Relaxin Receptor 1 Agonist, Attenuates Myocardial Infarction-Related Adverse Cardiac Remodeling in Mice.

Devarakonda T, Mauro AG, Guzman G, Hovsepian S, Cain C, Das A, Praveen P, Hossain MA, Salloum FN.

Journal of the American Heart Association · Volume and Issue Year 2020
First published 2020-04-16 · PMID 32295457
DOI 10.1161/jaha.119.015748

Animal Study2019 · Historical basic researchREF. 03

How does B7-33 release coating study fibrous capsules?

Research Findings

Coating of B7-33 reduces fibrous capsule thickness.[3] ↗

Study Design

Subcutaneous implantation of PLGA-coated materials in mice

Scope & Limitations

Local implantation coating, different from systemic injection.

View the Article Title and Full Citation+

Coatings Releasing the Relaxin Peptide Analogue B7-33 Reduce Fibrotic Encapsulation.

Welch NG, Mukherjee S, Hossain MA, Praveen P, Werkmeister JA, Wade JD, Bathgate RAD, Winkler DA, Thissen H.

ACS Applied Materials & Interfaces · Volume/Issue Year 2019
First published 2019-12-02 · PMID 31713411
DOI 10.1021/acsami.9b17859

i

Currently, 3 original studies related to the theme of this page have been selected. The number of studies includes different designs, populations, or preparations, not commercial clinical efficacy ratings. This page is a usage-oriented positive data selection, not a systematic review or dosing recommendation. Historical studies, combination preparations, and special models are all separately indicated.

GO DEEPER

What Questions Do These Studies Address?

Compare study populations, findings and scope.

↗
QUESTIONS, ANSWERED

B7-33 · Frequently Asked Questions.

What research findings does B7-33 have in fibrosis regulation?+

B7-33 reduces left ventricular fibrosis and improves some cardiovascular tissue indicators. Another study reports: reduces cell death and adverse remodeling, preserves heart function.[1] ↗ [2] ↗

Can anti-fibrosis research on B7-33 be directly applied to humans?+

Currently Not Possible. This involves animal myocardial remodeling and implant coating release; local materials and systemic intervention conditions differ and cannot be considered proof for human treatment.[1] ↗ [2] ↗ [3] ↗

B7-33—these conclusions apply to which study populations?+

Mouse isoproterenol cardiomyopathy model; mouse myocardial infarction and myocardial cells; subcutaneous implantation of PLGA-coated materials in mice. Preclinical; not equivalent to human heart failure efficacy.[1] ↗ [2] ↗ [3] ↗

VENTRO PEPTIDES & BIOTECH · RESEARCH PRODUCT RETAIL

Research peptides. Shop by product.

Compare specifications, reference prices and COA reports. Add products to your cart to request a quote.

Ventro Peptides & Biotech Logo
QUALITY DOCUMENTSCOA BY PRODUCTGLOBAL DELIVERYTECHNICAL SUPPORT

01 / CATALOG

Browse products

7 products Product names, specifications, and prices follow the current quotation
SemaglutideSM10COA

Images are illustrative. Actual specifications are as selected and confirmed in writing.

GLP-1 & Metabolic Research

Semaglutide

10mg/vial x 10vials

US$90.91
TirzepatideTR20COA

Images are illustrative. Actual specifications are as selected and confirmed in writing.

GLP-1 & Metabolic Research

Tirzepatide

20mg/vial x 10vials

US$160.61
RetatrutideRT10COA

Images are illustrative. Actual specifications are as selected and confirmed in writing.

GLP-1 & Metabolic Research

Retatrutide

10mg/vial x 10vials

US$109.09
BPC157BC10COA

Images are illustrative. Actual specifications are as selected and confirmed in writing.

Repair & Recovery Research

BPC157

10mg/vial x 10vials

US$133.33
MOTS-CMS20COA

Images are illustrative. Actual specifications are as selected and confirmed in writing.

Longevity & Mitochondrial Research

MOTS-C

20mg/vial x 10vials

US$257.58
LiraglutideLR10COA

Images are illustrative. Actual specifications are as selected and confirmed in writing.

GLP-1 & Metabolic Research

Liraglutide

10mg*10vials

US$164.71
IGF-lr3IG1COA

Images are illustrative. Actual specifications are as selected and confirmed in writing.

Growth Hormone & IGF-1

IGF-lr3

1mg/vial x 10vials

US$505.88

03 / ABOUT VENTRO

Reliable peptide supply, built for long-term partnerships.

Ventro supports research product retail purchases with clear pack specifications, available quality documents, and responsive international support.

  • High-purity peptides
  • Available COA reports
  • COA & quality documentation
  • Flexible small-quantity purchases
  • Reliable global fulfillment
  • Research product retail support

04 / QUALITY SYSTEM

Quality without compromise

Browse the available COA reports by product. Confirm documentation for your order with our team.

Controlled quality workflowRaw material to final release
Responsive global supportProduct matching and technical support

RESEARCH PRODUCT INQUIRY

Submit a product inquiry

Tell us the product, specification, and expected quantity. Our team will respond with pricing and available documents.

Use another email app

Opening an inquiry creates a draft, not a sent message. Review and press Send in Gmail, WhatsApp or your email app. Opening a channel passes the draft to the chosen provider. Privacy & cookies

Contact Ventro

Choose a channel to contact the Ventro team directly.

Use another email app

Opening an inquiry creates a draft, not a sent message. Review and press Send in Gmail, WhatsApp or your email app. Opening a channel passes the draft to the chosen provider. Privacy & cookies

WhatsApp